Overcome, a Program of Therapeutic Exercise and Functional Recovery to Improve the Functional Capacity of Women With Breast Cancer and Bone Metastases

Sponsor
Universidad de Granada (Other)
Overall Status
Recruiting
CT.gov ID
NCT05244382
Collaborator
(none)
58
1
2
23.8
2.4

Study Details

Study Description

Brief Summary

The research to be carried out is aimed at patients with metastatic breast cancer, specifically bone metastases. These patients will be recruited from two hospitals in Granada, provided they meet the established inclusion criteria. With this study, it is pretend to demonstrate the benefits of a program of therapeutic exercise and functional recovery of motor control with ultrasound feedback for the improvement of the functional capacity of the women eligible to participate in the study, as well as a positive impact on the quality of life of the patients other than their survival. The effect of the Overcome program will be compared with the usual treatment in this type of pathology. To do this, a pre-intervention evaluation and another at the end of the evaluation of the variables to be measured, such as functional capacity, will be carried out. In addition other evaluation will be carried out, after 6 months to assess the long-term effects.

In addition to the three main variables such as functional capacity and quality of life, another relationship of secondary variables will be studied, such as physical state, body composition or pain threshold, among others. This study in its entirety will be carried out by the "Oncology Patient Support Unit - Take Care" in the hands of a multidisciplinary team, carrying out the intervention protocolized by physiotherapists and occupational therapists.

Condition or Disease Intervention/Treatment Phase
  • Other: Overcome
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
58 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
OveRCoME: functiOnal Recovery Cancer MEtastasis
Actual Study Start Date :
Feb 7, 2022
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Feb 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Overcome group

Three-month multimodal program. Aerobic exercise will be combined with the use of TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy.

Other: Overcome
Multimodal program individualized and supervised 12 weeks duration (three months), with two sessions weekly face-to-face. This program will combine aerobic exercise in unloading through the use of the TRAG (AlterG® Anti-Gravity Treadmill®), functional recovery of motor control with feedback ultrasound and occupational therapy. Physical activity will be measured in parallel with the test. Likewise, the patients will be monitored by means of a heart rate sensor.

No Intervention: Usual treatment

Usual medical treatment for the same period of time

Outcome Measures

Primary Outcome Measures

  1. Functional capacity [Participants will be followed over 14 weeks]

    6-minute walking test

  2. Quality of life (QLQ) [Participants will be followed over 14 weeks]

    QLQ-C30 (Quality of Life of Cancer Patients) by the "European organization for reseach and treatment of cáncer quality life" (EORTC). This scale has 30 items, divided into a global health scale, 5 function subscales and 9 items/symptom scales. The scoring is obtained from through an Excel template.

Secondary Outcome Measures

  1. hand strength [Participants will be followed over 14 weeks]

    Hand dynamometry, for which a digital dynamometer (TKK) 5101 Grip-D; Takey, Tokyo, Japan)

  2. Lower limb strength [Participants will be followed over 14 weeks]

    sit-up text

  3. Body composition [Participants will be followed over 14 weeks]

    Height will be measured (cm). Weight (kg), body mass index, skeletal muscle mass, and body fat percentage will be obtained using bioelectrical impedance analysis (InBody 720; Biospace, Seoul, South Korea)

  4. Muscle architecture of multifidus muscle [Participants will be followed over 14 weeks]

    Muscle ultrasound and quantitative elastosonography will be performed of the multifidus muscle. We will obtain information in real time on the parameters related to the structural organization of the tissues (normal or abnormal elasticity) with respect to the adjacent tissue. of the multifidus muscle.

  5. Pain threshold on pressure, by algometry [Participants will be followed over 14 weeks]

    Electronic algometer (Somedic AB, Farsta, Sweden)

  6. Anxiety and depression [Participants will be followed over 14 weeks]

    "Hospital Anxiety and Depression Scale" (HADS). Composed of two subscales: Depression and Anxiety, each with seven items. The score of each subscale can vary between 0 and 21, since each item presents four response options, ranging from absence/minimal presence = 0, to maximum presence = 3.

  7. Opioid consumption and pain [Participants will be followed over 14 weeks]

    By the scale"Brief Pain Inventory-SF". This questionnaire consists of 15 items of which only two subscales are scored organized into mean pain intensity (items 3-6) and mean pain interference (items 9A-9G), the rest of the items do not score.

  8. Specific quality of life of the patient with bone metastasis [Participants will be followed over 14 weeks]

    QLQ-BM22 (quality of life questionnaire for bone metastases) by the "European organization for reseach and treatment of cáncer quality life" (EORTC). This questionnaire consists of 22 questions, which represent eight sections on symptom scales: five identify the painful sites, and three describe the characteristics of the pain; 14 headings represent functional scales: eight, of functional interferences, and six, refer to psychosocial aspects.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Having breast cancer controlled primary and occurrence of one or more bone lesions (metastases osteoblastic) with location in the pelvis, lumbar spine and / or thoracic, attributable to breast cancer

  2. The bone metastasis is located only at bone level (low neurological risk).

  3. Not having exercised regular physical during last 3 months.

  4. ECOG (Eastern Cooperative Oncology Group) ≤ 1.

  5. 4 weeks from a major surgery and full recovery.

Exclusion Criteria:
  1. Present cardiac toxicity secondary to treatments with decreased LVEF (If the LVEF percentage falls ≥ 10 points with respect to baseline or LVEF is below 50%) or QT prolongation

  2. Present any other toxicity greater than grade 2 in related to the treatments you are receiving or received in advance.

  3. Have spinal cord involvement, epidural involvement or instrumentation due to disease metastatic. (Moderate-high neurological risk)

  4. Have started or changed treatment hormonal during the last 3 months at recruitment.

  5. Present any pathology that prevents participation in a physical exercise program (PARQ-YOU).

  6. Present brain metastasis.

  7. Present uncontrolled hypertension (during recruitment, ≥2 / 3 evaluations <160/90 regardless of whether a regimen of antihypertensive therapy or not).

  8. Having had a serious cardiovascular event recently (in the last 12 months), including, but not limited to ischemic attack transient (TIA), cerebrovascular accident (CVA) or myocardial infarction (MI).

  9. Present a psychiatric illness, which would prevent the patient from signing the informed consent or adhere to the study protocol.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Faculty of Health Sciences Granada Spain 18016

Sponsors and Collaborators

  • Universidad de Granada

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mario Lozano-Lozano, Principal investigator, Universidad de Granada
ClinicalTrials.gov Identifier:
NCT05244382
Other Study ID Numbers:
  • Overcome project
First Posted:
Feb 17, 2022
Last Update Posted:
May 18, 2022
Last Verified:
May 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 18, 2022